Table 2.

Values of the FDG-PET/CT measures SUL, SUVbw, and TLG (mean ± SD) at baseline (scan 1) and after end of treatment week 40 (scan 2)

Variable	Liraglutide (N = 14) baseline	Placebo (N = 13) baseline	p-value baseline	Liraglutide (N = 14) Week 40	Placebo (N = 13) Week 40	p-value week 40
SUL1	0.31 ± 0.07	0.25 ± 0.06	NS	0.31 ± 0.07	0.26 ± 0.06	0.04
SUL2	0.31 ± 0.07	0.26 ± 0.06	NS	0.31 ± 0.07	0.26 ± 0.06	0.04
SUVbw1	0.49 ± 0.10	0.43 ± 0.10	NS	0.49 ± 0.10	0.43 ± 0.09	NS
SUVbw2	0.49 ± 0.10	0.43 ± 0.10	NS	0.49 ± 0.10	0.43 ± 0.10	NS
TLG1	899 ± 290	952 ± 177	NS	898 ± 279	941 ± 189	NS
TLG2	938 ± 291	998 ± 197	NS	935 ± 296	986 ± 205	NS

SUL, SUVbw and TLG obtained independently by rater 1 (suffix 1) and rater 2 (suffix 2). SUL: Standard Uptake Value corrected for lean body mass; SUVbw: Standard Uptake Value corrected for body weight; TLG: Total Lesion Glycolysis